Teva prices $2.3B multi-tranche senior notes offering to refinance existing debt

TEVA PHARMACEUTICAL INDUSTRIES LTD

Upsized offering from $2B to ~$2.3B equivalent across three tranches.
€1B 4.125% due 2031 (priced 99.349%), $500M 6.000% due 2032 (99.256%), $700M 5.750% due 2030 (99.418%).
Settlement expected May 28, 2025, subject to customary closing conditions.
Proceeds to fund tender offers for existing notes with coupons 3.15%-8.125% maturing 2026-2031.
Net proceeds may also be used for debt repayment at maturity, tender, or redemption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.